Abstract：
There is a need to further characterize the antibody response to vimentin in relation to its possible involvement in pathogenicity of sarcoidosis and other lung disorders.
OBJECTIVE: We investigated serum samples from patients with sarcoidosis, healthy controls and controls with other non-infectious lung diseases., to evaluate levels and frequency of these antibodies.
METHODS: A retrospective-prospective comparative study was performed in the years 2015-2019. Sera from 93 patients with sarcoidosis, 55 patients with non-infectious lung diseases and 40 healthy subjects was examined for presence of autoantibodies to mutated citrullinated vimentin (anti-MCV). Patients with elevated anti-MCV levels were tested for antibodies to a cyclic citrullinated peptide (anti-CCP) and citrullinated vimentin (anti-Sa). In all cases ELISA assays was used. The results were considered statistically significant at p-value less than 0.05.
RESULTS: The high concentrations of anti-MCV antibodies were more frequent in patients with sarcoidosis (40.9% of the cases, 38/93), compared to the control groups (23.6% and 25.0% of cases, respectively). In sarcoidosis, clinical symptoms similar to the autoimmune pathology were described. A moderate positive correlation between the anti-MCV and anti-Sa antibodies (r = 0.66) was found in 13 patients with sarcoidosis. There was no significant difference between the levels of the anti-MCV and the anti-CCP in patients with non-infectious lung diseases and the healthy control group.
CONCLUSIONS: Antibodies to citrullinated cyclic peptides are not significant in the pathogenesis of sarcoidosis and other investigated pulmonary diseases (COPD, granulomatosis with polyangiitis, alveolitis) and based on their low concentration, it can be assumed that citrullination and modification of vimentin is not a key factor in the development of an autoimmune response in patients with sarcoidosis.
OBJECTIVE: We investigated serum samples from patients with sarcoidosis, healthy controls and controls with other non-infectious lung diseases., to evaluate levels and frequency of these antibodies.
METHODS: A retrospective-prospective comparative study was performed in the years 2015-2019. Sera from 93 patients with sarcoidosis, 55 patients with non-infectious lung diseases and 40 healthy subjects was examined for presence of autoantibodies to mutated citrullinated vimentin (anti-MCV). Patients with elevated anti-MCV levels were tested for antibodies to a cyclic citrullinated peptide (anti-CCP) and citrullinated vimentin (anti-Sa). In all cases ELISA assays was used. The results were considered statistically significant at p-value less than 0.05.
RESULTS: The high concentrations of anti-MCV antibodies were more frequent in patients with sarcoidosis (40.9% of the cases, 38/93), compared to the control groups (23.6% and 25.0% of cases, respectively). In sarcoidosis, clinical symptoms similar to the autoimmune pathology were described. A moderate positive correlation between the anti-MCV and anti-Sa antibodies (r = 0.66) was found in 13 patients with sarcoidosis. There was no significant difference between the levels of the anti-MCV and the anti-CCP in patients with non-infectious lung diseases and the healthy control group.
CONCLUSIONS: Antibodies to citrullinated cyclic peptides are not significant in the pathogenesis of sarcoidosis and other investigated pulmonary diseases (COPD, granulomatosis with polyangiitis, alveolitis) and based on their low concentration, it can be assumed that citrullination and modification of vimentin is not a key factor in the development of an autoimmune response in patients with sarcoidosis.
摘要：
需要进一步表征对波形蛋白的抗体应答与其可能参与结节病和其他肺部疾病的致病性有关。
目的：我们调查了结节病患者的血清样本，健康对照和其他非传染性肺病对照。,评估这些抗体的水平和频率。
方法：在2015-2019年进行了一项回顾性前瞻性比较研究。93例结节病患者的血清，检查55名非感染性肺病患者和40名健康受试者是否存在针对突变型瓜氨酸化波形蛋白(抗MCV)的自身抗体。测试抗MCV水平升高的患者的针对环状瓜氨酸化肽(抗CCP)和瓜氨酸化波形蛋白(抗Sa)的抗体。在所有情况下,使用ELISA测定。结果在p值小于0.05时被认为是统计学上显著的。
结果：结节病患者中高浓度的抗MCV抗体更为常见（40.9％的病例，38/93），与对照组相比(23.6%和25.0%的病例，分别)。在结节病中，描述了与自身免疫病理学相似的临床症状。在13例结节病患者中发现抗MCV和抗Sa抗体之间呈中度正相关（r=0.66）。非感染性肺部疾病患者的抗MCV和抗CCP水平与健康对照组无明显差异。
结论：瓜氨酸环肽抗体在结节病和其他研究的肺部疾病的发病机理中并不重要（COPD，肉芽肿性多血管炎，肺泡炎)，并基于它们的低浓度，可以假设瓜氨酸化和波形蛋白修饰不是结节病患者自身免疫反应发展的关键因素。
目的：我们调查了结节病患者的血清样本，健康对照和其他非传染性肺病对照。,评估这些抗体的水平和频率。
方法：在2015-2019年进行了一项回顾性前瞻性比较研究。93例结节病患者的血清，检查55名非感染性肺病患者和40名健康受试者是否存在针对突变型瓜氨酸化波形蛋白(抗MCV)的自身抗体。测试抗MCV水平升高的患者的针对环状瓜氨酸化肽(抗CCP)和瓜氨酸化波形蛋白(抗Sa)的抗体。在所有情况下,使用ELISA测定。结果在p值小于0.05时被认为是统计学上显著的。
结果：结节病患者中高浓度的抗MCV抗体更为常见（40.9％的病例，38/93），与对照组相比(23.6%和25.0%的病例，分别)。在结节病中，描述了与自身免疫病理学相似的临床症状。在13例结节病患者中发现抗MCV和抗Sa抗体之间呈中度正相关（r=0.66）。非感染性肺部疾病患者的抗MCV和抗CCP水平与健康对照组无明显差异。
结论：瓜氨酸环肽抗体在结节病和其他研究的肺部疾病的发病机理中并不重要（COPD，肉芽肿性多血管炎，肺泡炎)，并基于它们的低浓度，可以假设瓜氨酸化和波形蛋白修饰不是结节病患者自身免疫反应发展的关键因素。
